Finally, ILK has been widely suggested as a potential therapeutic target not only in human malignancies [40, 153, 155, 157, 158, 222], but also in fibrosis of kidney [166], lung [168], prostate [169], or bladder cancer [170]; Alzheimer disease [180]; inflammatory renal diseases [196]; nephrogenic diabetes insipidus (NDI) [199] or cardiovascular diseases [20, 72, 146]. This evidence concerns the gene ILK and early-onset autosomal dominant Alzheimer disease.